SCHEMBL2610304

SCHEMBL2610304

CC(=O)c1ccc(Cc2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.67
LMNA P02545 1/20 0.60
KMT2A Q03164 2/20 0.58
MEN1 O00255 1/20 0.52
NR4A2 P43354 1/20 0.50
MLYCD O95822 1/20 0.50
HDAC6 Q9UBN7 1/20 0.49
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
ACP3 P15309 1/20 0.49
TP53 P04637 1/20 0.48
GPR52 Q9Y2T5 1/20 0.48
SRD5A2 P31213 1/20 0.48
CES2 O00748 1/20 0.47
LTA4H P09960 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2721465 0.86 NR4A2 (0.66) MAOBKMT2AMEN1NR4A2MLYCD
SCHEMBL2128961 0.84 MAOB (0.52) MAOBNR4A2MLYCDMAPTHDAC1
SCHEMBL2610303 0.84 KMT2A (0.70) MAOBLMNAKMT2AMEN1NR4A2
SCHEMBL28036036 0.84 LMNA (0.78) MAOBLMNAKMT2AHDAC6MAPT
SCHEMBL20463439 0.80 MAOB (1.00) MAOBNR4A2MAPTHTTL3MBTL1
SCHEMBL3237564 0.80 TAAR1 (0.64) MAOBLMNAMAPTACP3LTA4H
SCHEMBL21165039 0.79 MAPT (0.58) MAOBLMNAMAPTACP3LTA4H
SCHEMBL9885484 0.79 IDO1 (0.54) MAOBMAPTHDAC1HDAC8ACP3
SCHEMBL30370514 0.78 TAAR1 (0.58) KMT2AMEN1MAPTACP3LTA4H
SCHEMBL7435425 0.78 TAAR1 (0.58) KMT2AMEN1MAPTACP3LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748417-B2 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2014-06-10 US disclosed
US-8575363-B2 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2013-11-05 US disclosed
US-20130244998-A1 PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2013-09-19 US disclosed
US-8513423-B2 Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2013-08-20 US disclosed
US-20130196970-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2013-08-01 US disclosed
US-20130102584-A1 PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2013-04-25 US disclosed
US-20120101081-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2012-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196970-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, MGLL MAOB 347/4885LMNA 1887/4885KMT2A 1314/4885
US-20120101081-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, MGLL MAOB 347/4885LMNA 1887/4885KMT2A 1314/4885
US-20130102584-A1 PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, MGLL MAOB 387/4885LMNA 1900/4885KMT2A 961/4885
US-20130244998-A1 PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLCEROL LIPASE INHIBITORS MGLL, PNLIP, LPL MAOB 1036/4885LMNA 1745/4885KMT2A 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.